Zoladex 3.6mg leaving the PBS in November — what women on goserelin need to know

What happened

The Pharmaceutical Benefits Scheme published notice this month that goserelin 3.6mg implant (Zoladex) will be removed from the PBS on 1 November 2026. AstraZeneca requested the delisting. The stated reason: commercial. Not clinical. Not safety. Not the arrival of a superior alternative. A commercial decision about market viability.

For the woman reading this because she just got a letter from her oncologist or gynaecologist and typed “Zoladex PBS” into the search bar: the reason matters. Your medicine is not being withdrawn because it stopped working. The system is making a commercial decision about your body, and that is a different problem from a clinical one. The clinical problem — whether you have a path forward — is solvable for most indications. The commercial decision is not yours to fix.

Zoladex (goserelin) is a GnRH agonist. It works by signalling the pituitary gland to stop stimulating oestrogen production from the ovaries, inducing a temporary, reversible low-oestrogen state. That mechanism is useful in at least four clinical settings: endometriosis, where reducing oestrogen suppresses disease activity; hormone receptor-positive breast cancer in premenopausal women, where ovarian suppression adds to the effect of endocrine therapy; anticipated premature ovarian failure during chemotherapy, where suppressing the ovaries may offer some protective effect on fertility; and prostate cancer, where lowering testosterone — which follows from GnRH suppression — slows disease progression. Each of these settings has a different answer to the question “what happens after November?”

The both-and

Two things are simultaneously true here, and they point in different directions depending on which indication you are in.

The first: for endometriosis and prostate cancer, the clinical pathway does not close on 1 November. The PBAC has confirmed that alternatives remain PBS-listed — including the goserelin 10.8mg depot implant (Zoladex 10.8 Implant) and other GnRH agonists. The 10.8mg format administers quarterly rather than monthly, which changes the clinic schedule. For most patients in these indications, the formulation change is clinically manageable. A specialist or GP conversation can confirm whether it suits the individual clinical picture.

The second: for hormone receptor-positive breast cancer and anticipated premature ovarian failure, the situation is materially different. As Breast Cancer Network Australia has raised since the announcement, there is currently no other PBS-listed option covering these indications in the 3.6mg monthly format. The PBAC acknowledged this as an unmet clinical need. AstraZeneca has made two commitments in response: a free patient access program beginning 1 November 2026 for eligible patients without suitable alternatives, running for an initial six months with review; and an application to expand the indication for the 10.8mg implant to cover hormone receptor-positive breast cancer patients.

An application is not an approval. A six-month access program is not indefinite access. Both commitments require follow-through, and neither yet has a confirmed outcome for 2027 and beyond.

USANZ has also flagged the discontinuation from the urology perspective. For prostate cancer patients who have used the monthly 3.6mg format because it suited their clinical management, the 10.8mg quarterly alternative is well-established with a clear clinical evidence base. For this group, the transition is the most straightforward of all the affected indications.

2 cents

November is five months away. That feels like time. For the breast cancer and ovarian failure indication groups, it is not comfortable time.

If your indication is endometriosis: the clinical path is navigable, but formulation changes are not automatic. A conversation with your GP or gynaecologist about whether the 10.8mg quarterly format suits your situation is worth having before October — not as a panic measure, but as practical planning. The 10.8mg format is well-established for endometriosis management and has its own track record.

If your indication is hormone receptor-positive breast cancer: this is where the gap is real. AstraZeneca’s access program will open from November, but its eligibility criteria are not yet fully published. Getting onto that program from day one — rather than managing an urgent gap after November — is worth a proactive conversation with your oncologist now. Do not wait until October.

If your indication is ovarian failure preservation during chemotherapy: the same applies. Your fertility or reproductive medicine specialist is the right starting point. The access program may cover you; that conversation needs to happen in advance, not at the point of crisis.

This is not a minor administrative inconvenience. For the women using Zoladex 3.6mg as part of breast cancer treatment or fertility protection, it is a question about uninterrupted access to a treatment embedded in their management plan. The system made a commercial decision. The response is a conversation with your treating team — the sooner the better.

This is general information, not personal medical advice. Your indication, your treatment history, and your alternative options are specific to your clinical picture — that assessment happens with your treating specialist, not on a website.

Verdict

Verdict: yes — worth knowing about.

The Zoladex 3.6mg delisting is a commercial decision with unequal consequences across indications. For most patients — endometriosis, prostate cancer — PBS-listed alternatives exist and the transition is manageable. For hormone receptor-positive breast cancer and anticipated premature ovarian failure, the PBAC has acknowledged an unmet clinical need, and the access program and expanded-indication application are the current plan, with outcomes still pending. If this is your situation, the conversation with your treating team is worth starting now.

---

Sources cited

1. PBS — Delisting of goserelin 3.6mg implant (Zoladex Implant™) from the PBS — 1 November 2026
2. Breast Cancer Network Australia — Update on access to Zoladex treatment
3. USANZ — Discontinuation of ZOLADEX Implant in Australia (April 2026)